{
    "xml": "<topic id=\"PHP4216\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/vildagliptin\" basename=\"vildagliptin\" title=\"VILDAGLIPTIN\">\n<title>VILDAGLIPTIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1113\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/vildagliptin\">Vildagliptin</xref>\n</p>\n<data name=\"vtmid\">428807006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_617518759\" title=\"Dipeptidylpeptidase-4 inhibitors (gliptins)\">Dipeptidylpeptidase-4 inhibitors (gliptins)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP41250\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/vildagliptin\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41229\" outputclass=\"indicationsAndDose\" rev=\"1.12\" parent=\"/drugs/vildagliptin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus as monotherapy (if metformin inappropriate)</p>\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with metformin or pioglitazone (when treatment with either metformin or pioglitazone fails to achieve adequate glycaemic control)</p>\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control)</p>\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus in combination with sulfonylurea (if metformin inappropriate)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg daily, dose to be taken in the morning.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41256\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/vildagliptin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ketoacidosis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41261\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/vildagliptin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Manufacturer advises avoid in severe heart failure&#8212;no information available</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41224\" outputclass=\"interactions\" rev=\"1.3\" parent=\"/drugs/vildagliptin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41178\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/vildagliptin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Asthenia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">tremor</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatic dysfunction</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Nasopharyngitis</ph>; <ph outputclass=\"sideEffect\">upper respiratory tract infection</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bullous skin reactions</ph>; <ph outputclass=\"sideEffect\">exfoliative skin reactions</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Pancreatitis</p>\n<p>Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Rare reports of liver dysfunction; discontinue if jaundice or other signs of liver dysfunction occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41216\" outputclass=\"pregnancy\" parent=\"/drugs/vildagliptin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41268\" outputclass=\"breastFeeding\" parent=\"/drugs/vildagliptin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41239\" outputclass=\"hepaticImpairment\" parent=\"/drugs/vildagliptin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41198\" outputclass=\"renalImpairment\" parent=\"/drugs/vildagliptin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose to 50&#8239;mg once daily if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41143\" outputclass=\"monitoringRequirements\" parent=\"/drugs/vildagliptin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function before treatment and every 3 months for first year and periodically thereafter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41206\" outputclass=\"patientAndCarerAdvice\" rev=\"1.11\" parent=\"/drugs/vildagliptin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Patients should be advised to seek prompt medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41118\" outputclass=\"nationalFunding\" rev=\"1.7\" parent=\"/drugs/vildagliptin\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised that vildagliptin (<i>Galvus</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when treatment with metformin or a sulfonylurea is inappropriate (December 2012), and in combination with metformin when addition of a sulfonylurea is inappropriate (March 2008), and in combination with a sulfonylurea if metformin is inappropriate (September 2009), and also as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4216-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/vildagliptin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76034\" title=\"Tablet\" namespace=\"/drugs/vildagliptin/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85629\" namespace=\"/drugs/metformin-with-vildagliptin\" title=\"METFORMIN WITH VILDAGLIPTIN\" count=\"1\" rel=\"backlink\">METFORMIN WITH VILDAGLIPTIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"4\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1113\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/vildagliptin\" title=\"Vildagliptin\" count=\"1\" rel=\"link\">Vildagliptin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76034\" namespace=\"/drugs/vildagliptin/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4216",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/vildagliptin",
    "basename": "vildagliptin",
    "title": "VILDAGLIPTIN",
    "interactants": [
        {
            "id": "bnf_int_1113",
            "label": "Vildagliptin"
        }
    ],
    "vtmid": "428807006",
    "drugClassification": [
        "Dipeptidylpeptidase-4 inhibitors (gliptins)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.",
                "html": "<p>Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus as monotherapy (if metformin inappropriate)",
                        "html": "Type 2 diabetes mellitus as monotherapy (if metformin inappropriate)"
                    },
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with metformin or pioglitazone (when treatment with either metformin or pioglitazone fails to achieve adequate glycaemic control)",
                        "html": "Type 2 diabetes mellitus in combination with metformin or pioglitazone (when treatment with either metformin or pioglitazone fails to achieve adequate glycaemic control)"
                    },
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control)",
                        "html": "Type 2 diabetes mellitus in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control)"
                    },
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control",
                        "html": "Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "50 mg twice daily.",
                        "html": "<p>50&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus in combination with sulfonylurea (if metformin inappropriate)",
                        "html": "Type 2 diabetes mellitus in combination with sulfonylurea (if metformin inappropriate)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "50 mg daily, dose to be taken in the morning.",
                        "html": "<p>50&#8239;mg daily, dose to be taken in the morning.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose of concomitant sulfonylurea or insulin may need to be reduced.",
                "html": "<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ketoacidosis",
                "html": "Ketoacidosis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Manufacturer advises avoid in severe heart failure&#8212;no information available",
                "html": "Manufacturer advises avoid in severe heart failure&#8212;no information available"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Asthenia",
                        "html": "Asthenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Arthralgia",
                        "html": "Arthralgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypoglycaemia",
                        "html": "hypoglycaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hepatic dysfunction",
                        "html": "Hepatic dysfunction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Nasopharyngitis",
                        "html": "Nasopharyngitis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "upper respiratory tract infection",
                        "html": "upper respiratory tract infection",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Bullous skin reactions",
                        "html": "Bullous skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "exfoliative skin reactions",
                        "html": "exfoliative skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Pancreatitis",
                "textContent": "Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).",
                "html": "<p>Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).</p>"
            },
            {
                "type": "advice",
                "title": "Liver toxicity",
                "textContent": "Rare reports of liver dysfunction; discontinue if jaundice or other signs of liver dysfunction occur.",
                "html": "<p>Rare reports of liver dysfunction; discontinue if jaundice or other signs of liver dysfunction occur.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose to 50 mg once daily if eGFR less than 50 mL/minute/1.73 m2.",
                "html": "<p>Reduce dose to 50&#8239;mg once daily if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function before treatment and every 3 months for first year and periodically thereafter.",
                "html": "<p>Monitor liver function before treatment and every 3 months for first year and periodically thereafter.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Liver toxicity",
                "textContent": "Patients should be advised to seek prompt medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop.",
                "html": "<p>Patients should be advised to seek prompt medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised that vildagliptin (Galvus ) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when treatment with metformin or a sulfonylurea is inappropriate (December 2012), and in combination with metformin when addition of a sulfonylurea is inappropriate (March 2008), and in combination with a sulfonylurea if metformin is inappropriate (September 2009), and also as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised that vildagliptin (<i>Galvus</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when treatment with metformin or a sulfonylurea is inappropriate (December 2012), and in combination with metformin when addition of a sulfonylurea is inappropriate (March 2008), and in combination with a sulfonylurea if metformin is inappropriate (September 2009), and also as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76034",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85629",
                "label": "METFORMIN WITH VILDAGLIPTIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1113",
                "label": "Vildagliptin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76034",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}